Contact Us

Victoria's Secret rapes Mother Earth : Sex fuelled money fells forests for catalogs paper from downed trees :
20061215 : December 15, 2006

The company named Victoria's Secret has 'pledged' to use 10% recycled paper in producing their millions of catalogs.
This means the company is currently using 100% virgin forest, killing living trees to create paper for their catalogs.
If and when they honor their pledge for 10% recycle paper use, they will still kill trees for 90% of their catalogs.

Also in the news : December 17, 2006

Eli Lilly Said to Play Down Risk of Top Pill


The drug maker Eli Lilly has engaged in a decade-long effort to play  down the health risks of Zyprexa, its best-selling medication for  schizophrenia, according to hundreds of internal Lilly documents and  e-mail messages among top company managers.

The documents, given to The Times by a lawyer representing mentally  ill patients, show that Lilly executives kept important information  from doctors about Zyprexa’s links to obesity and its tendency to  raise blood sugar — both known risk factors for diabetes.

Lilly’s own published data, which it told its sales representatives  to play down in conversations with doctors, has shown that 30 percent  of patients taking Zyprexa gain 22 pounds or more after a year on the  drug, and some patients have reported gaining 100 pounds or more. But  Lilly was concerned that Zyprexa’s sales would be hurt if the company  was more forthright about the fact that the drug might cause  unmanageable weight gain or diabetes, according to the documents,  which cover the period 1995 to 2004.

Zyprexa has become by far Lilly’s best-selling product, with sales of  $4.2 billion last year, when about two million people worldwide took  the drug.

Critics, including the American Diabetes Association, have argued  that Zyprexa, introduced in 1996, is more likely to cause diabetes  than other widely used schizophrenia drugs. Lilly has consistently  denied such a link, and did so again on Friday in a written response  to questions about the documents. The company defended Zyprexa’s  safety, and said the documents had been taken out of context.

But as early as 1999, the documents show that Lilly worried that side  effects from Zyprexa, whose chemical name is olanzapine, would hurt  sales.

“Olanzapine-associated weight gain and possible hyperglycemia is a  major threat to the long-term success of this critically important  molecule,” Dr. Alan Breier wrote in a November 1999 e-mail message to  two-dozen Lilly employees that announced the formation of an  “executive steering committee for olanzapine-associated weight  changes and hyperglycemia.” Hyperglycemia is high blood sugar.

At the time Dr. Breier, who is now Lilly’s chief medical officer, was  the chief scientist on the Zyprexa program.

In 2000, a group of diabetes doctors that Lilly had retained to  consider potential links between Zyprexa and diabetes warned the  company that “unless we come clean on this, it could get much more  serious than we might anticipate,” according to an e-mail message  from one Lilly manager to another.

And in that year and 2001, the documents show, Lilly’s own marketing  research found that psychiatrists were consistently saying that many  more of their patients developed high blood sugar or diabetes while  taking Zyprexa than other antipsychotic drugs.

The documents were collected as part of lawsuits on behalf of  mentally ill patients against the company. Last year, Lilly agreed to  pay $750 million to settle suits by 8,000 people who claimed they  developed diabetes or other medical problems after taking Zyprexa.  Thousands more suits against the company are pending.

On Friday, in its written response, Lilly said that it believed that  Zyprexa remained an important treatment for patients with  schizophrenia and bipolar disorder. The company said it had given the  Food and Drug Administration all its data from clinical trials and  reports of adverse events, as it is legally required to do. Lilly  also said it shared data from literature reviews and large studies of  Zyprexa’s real-world use.

“In summary, there is no scientific evidence establishing that  Zyprexa causes diabetes,” the company said.

Lilly also said the documents should not have been made public  because they might “cause unwarranted fear among patients that will  cause them to stop taking their medication.”

As did similar documents disclosed by the drug maker Merck last year  in response to lawsuits over its painkiller Vioxx, the Lilly  documents offer an inside look at how a company marketed a drug while  seeking to play down its side effects. Lilly, based in Indianapolis,  is the sixth-largest American drug maker, with $14 billion in revenue  last year.

The documents — which include e-mail, marketing material, sales  projections and scientific reports — are replete with references to  Zyprexa’s importance to Lilly’s future and the need to keep concerns  about diabetes and obesity from hurting sales. But that effort became  increasingly difficult as doctors saw Zyprexa’s side effects, the  documents show.

In 2002, for example, Lilly rejected plans to give psychiatrists  guidance about how to treat diabetes, worrying that doing so would  tarnish Zyprexa’s reputation. “Although M.D.’s like objective,  educational materials, having our reps provide some with diabetes  would further build its association to Zyprexa,” a Lilly manager  wrote in a March 2002 e-mail message.

But Lilly did expand its marketing to primary care physicians, who  its internal studies showed were less aware of Zyprexa’s side  effects. Lilly sales material encouraged representatives to promote  Zyprexa as a “safe, gentle psychotropic” suitable for people with  mild mental illness.

Some top psychiatrists say that Zyprexa will continue to be widely  used despite its side effects, because it works better than most  other antipsychotic medicines in severely ill patients. But others  say that Zyprexa appears no more effective overall than other medicines.

And some doctors who specialize in diabetes care dispute Lilly’s  assertion that Zyprexa does not cause more cases of diabetes than  other psychiatric drugs. “When somebody gains weight, they need more  insulin, they become more insulin resistant,” Dr. Joel Zonszein, the  director of the clinical diabetes center at Montefiore Medical Center  in the Bronx, said when asked about the drug.

In 2003, after reviewing data provided by Lilly and other drug  makers, the F.D.A. said that the current class of antipsychotic drugs  may cause high blood sugar. It did not specifically single out  Zyprexa, nor did it say that the drugs had been proven to cause  diabetes.

The drugs are known as atypical antipsychotics and include Johnson &  Johnson’s Risperdal and AstraZeneca’s Seroquel. When they were  introduced in the mid-1990s, psychiatrists hoped they would relieve  mental illness without the tremors and facial twitches associated  with older drugs. But the new drugs have not proven significantly  better and have their own side effects, said Dr. Jeffrey Lieberman,  the lead investigator on a federally sponsored clinical trial that  compared Zyprexa and other new drugs with one older one.

The Zyprexa documents were provided to the Times by James B.  Gottstein, a lawyer who represents mentally ill patients and has sued  the state of Alaska over its efforts to force patients to take  psychiatric medicines against their will. Mr. Gottstein said the  information in the documents raised public health issues.

“Patients should be told the truth about drugs like Zyprexa,” Mr.  Gottstein said.

Lilly originally provided the documents, under seal, to plaintiffs  lawyers who sued the company claiming their clients developed  diabetes from taking Zyprexa. Mr. Gottstein, who is not subject to  the confidentiality agreement that covers the product liability  suits, subpoenaed the documents in early December from a person  involved in the suits.

In its statement, Lilly called the release of the documents  “illegal.” The company said it could not comment on specific  documents because of the continuing product liability suits.

In some ways, the Zyprexa documents are reminiscent of those produced  in litigation over Vioxx, which Merck stopped selling in 2004 after a  clinical trial proved it caused heart problems. They treat very  different conditions, but Zyprexa and Vioxx are not entirely  dissimilar. Both were thought to be safer than older and cheaper  drugs, becoming bestsellers as a result, but turned out to have  serious side effects.

After being pressed by doctors and regulators, Merck eventually did  test Vioxx’s cardiovascular risks and withdrew the drug after finding  that Vioxx increased heart attacks and strokes.

Lilly has never conducted a clinical trial to determine exactly how  much Zyprexa raises patients’ diabetes risks. But scientists say  conducting such a study would be exceedingly difficult, because  diabetes takes years to develop, and it can be hard to keep mentally  ill patients enrolled in a clinical trial.

When it was introduced, Zyprexa was the third and most heralded of  the atypical antipsychotics. With psychiatrists eager for new  treatments for schizophrenia, bipolar disorder, and dementia,  Zyprexa’s sales soared.

But as sales grew, reports rolled in to Lilly and drug regulators  that the medicine caused massive weight gain in many patients and was  associated with diabetes. For example, a California doctor reported  that 8 of his 35 patients on Zyprexa had developed high blood sugar,  including two who required hospitalization.

The documents show that Lilly encouraged its sales representatives to  play down those effects when talking to doctors. In one 1998  presentation, for example, Lilly said its salespeople should be told,  “Don’t introduce the issue!!!” Meanwhile, the company researched  combinations of Zyprexa with several other drugs, hoping to alleviate  the weight gain. But the combinations failed.

To reassure doctors, Lilly also publicly said that when it followed  up with patients who had taken Zyprexa in a clinical trial for three  years, it found that weight gain appeared to plateau after about nine  months. But the company did not discuss a far less reassuring finding  in early 1999, disclosed in the documents, that blood sugar levels in  the patients increased steadily for three years.

In 2000 and 2001, more warning signs emerged, the documents show. In  four surveys conducted by Lilly’s marketing department, the company  found that 70 percent of psychiatrists polled had seen at least one  of their patients develop high blood sugar or diabetes while taking  Zyprexa, compared with about 20 percent for Risperdal or Seroquel.  Lilly never disclosed those findings.

By mid-2003, Lilly began to change its stance somewhat, publicly  acknowledging that Zyprexa can cause severe obesity. Marketing  documents make clear that by then Lilly believed it had no choice. On  June 23, 2003, an internal committee reported that Zyprexa sales were  “below plan” and that doctors were “switching/avoiding Zyprexa.”

Since then, Lilly has acknowledged Zyprexa’s effect on weight but has  argued that it does not necessarily correlate to diabetes. But  Zyprexa’s share of antipsychotic drug prescriptions is falling, and  some psychiatrists say they no longer believe the information Lilly  offers.

“From my personal experience, at first my concerns about weight gain  with this drug were very significantly downplayed by their field  representatives,” said Dr. James Phelps, a psychiatrist in Corvallis,  Or. ‘Their continued efforts to downplay that, I think in retrospect,  was an embarrassment to the company.”

Dr. Phelps says that he tries to avoid Zyprexa because of its side  effects but sometimes still prescribes it, especially when patients  are acutely psychotic and considering suicide, because it works  faster than other medicines.

“I wind up using it as an emergency medicine, where it’s superb,” he  said. “But I’m trying to get my patients off of Zyprexa, not put them on.”

- end - More info on PsychRights see


We have added many pages since then and we have many pages without sponsor.
Yes, that is an invitation to you, Dear Reader, to be a member sponsor of one
or more pages of Star Arts at Good Works On Earth hundreds of sharings.



Good Works On Earth
All Rights ReServed World Wise
Burnishings to the Gold Standard began on : 20051213

This page was last updated in some way on : 20100107